Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

BACKGROUND: Phase 2 trial endpoints that can be utilized in high-risk biochemical recurrence (BCR) after prostatectomy as a way of more rapidly identifying treatments for phase 3 trials are urgently needed. The efficacy of abiraterone acetate plus prednisone (AAP) in BCR is unknown. OBJECTIVE: To co...

Descripción completa

Detalles Bibliográficos
Autores principales: Autio, Karen A., Antonarakis, Emmanuel S., Mayer, Tina M., Shevrin, Daniel H., Stein, Mark N., Vaishampayan, Ulka N., Morris, Michael J., Slovin, Susan F., Heath, Elisabeth I., Tagawa, Scott T., Rathkopf, Dana E., Milowsky, Matthew I., Harrison, Michael R., Beer, Tomasz M., Balar, Arjun V., Armstrong, Andrew J., George, Daniel J., Paller, Channing J., Apollo, Arlyn, Danila, Daniel C., Graff, Julie N., Nordquist, Luke, Dayan Cohn, Erica S., Tse, Kin, Schreiber, Nicole A., Heller, Glenn, Scher, Howard I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Prostate Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655386/
https://www.ncbi.nlm.nih.gov/pubmed/34934969
http://dx.doi.org/10.1016/j.euros.2021.09.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655386/
https://www.ncbi.nlm.nih.gov/pubmed/34934969
http://dx.doi.org/10.1016/j.euros.2021.09.015

Ejemplares similares